Conference on Analgesic Trials
The cost for APS CAT is $150 and includes lunch and refreshments. Preregistration is required. The event is a full day, approximately 8AM-4:30PM.
Join us for the third annual APS Conference on Analgesic Trials happening March 4, 2018, one day before the start of the Scientific Summit at the Disneyland Hotel® in Anaheim, CA. This will be chaired and moderated by Neil Singla, MD, APS Clinical Trials special interest group chair and chief scientific officer of Lotus Clinical Research.
Hundreds of pain researchers have attended the first and second annual APS-CAT conferences, discussing design and conduct of analgesic clinical trials with expert panels. Audience feedback has been overwhelmingly positive both years.
APS-CAT 2018 presenters include:
Robert Dworkin, PhD
Director, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION)
Overcoming False Positive and Negative Results in Chronic Pain Clinical Trials: We’re Going to Need a Bigger (or Better) Boat
Neil Singla, MD
Chief Scientific Officer, Lotus Clinical Research
Mitigation of Placebo Response through Subject and Investigator Training
Robert Rappaport, MD
Founder, Analgesic Concepts
Former Director, FDA Division of Anesthesia, Analgesia, and Addiction Products
Getting the Indication You Want: Selecting an Appropriate Analgesic Model
Nathaniel Katz, MD
CEO, Analgesic Solutions
Using Central Statistical Surveillance to Monitor and Correct Problems that Impact Assay Sensitivity: Recent Findings
John Farrar, MD PhD
Associate Professor, University of Pennsylvania
Co-Director, Biostatistics Analysis Center, Biostatistical and Epidemiology Consulting Center, Center for Clinical Epidemiology and Biostatistics
Determining if a Chronic Pain Subject Should Be Randomized: Variability in Baseline Pain Diary Data and Other Factors that Affect Assay Sensitivity
Roy Freeman, MD
Professor of Neurology, Harvard Medical School
Director, Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center
Small Fiber Neuropathy: Implications for Clinical Trials and Drug Development
Ralf Baron, MD
Head, Division of Neurological Pain Research and Therapy; Vice Chair, Department of Neurology, Christian-Albrechts-Universitaet
Phenotyping of Neuropathic Pain Patients: Implications for Clinical Trial Design and Drug Development
APS-CAT is a full-day conference focused on optimizing the design and conduct of analgesic clinical trials. APS-CAT involves audience members in dialogue with thought leaders in the field to disseminate the latest scientific and regulatory developments and facilitate collaboration. The conference features a panel format, with each presenter speaking for 30 minutes followed by Q & A. Our goal is to maximize the efficiency of analgesic drug development.
You can register for the full APS Summit, which offers 2 additional days of excellent scientific content, or select “Pre-Con Only”.
Schedule |
Sunday, March 4, 2018 |
|---|---|
| 7:30-8am | Registration and Breakfast |
| 8am | Opening Remarks: Neil Singla, MD APS Clinical Trials SIG Chair |
| 8:15am | Using Central Statistical Surveillance to Monitor and Correct Problems that Impact Assay Sensitivity: Recent Findings Nathaniel Katz, MD President, Analgesic Solutions |
| 8:45am | Panel Discussion / Q & A |
| 9:15am | Overcoming False Positive and Negative Results in Chronic Pain Clinical Trials: We’re Going to Need a Bigger (or Better) Boat Robert Dworkin, MD Director, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) |
| 9:45am | Panel Discussion / Q & A |
| 10:15am | Break |
| 10:45am | Getting the Indication You Want: Selecting an Appropriate Analgesic Model Robert Rappaport, MD Former Director, FDA Division of Anesthesia, Analgesia, and Addiction Products |
| 11:15am | Panel Discussion / Q & A |
| 11:45am | Determining if a Chronic Pain Subject Should Be Randomized: Variability in Baseline Pain Diary Data and Other Factors that Affect Assay Sensitivity John Farrar, MD Associate Professor, University of Pennsylvania; Co-Director, Biostatistics Analysis Center, Biostatistical and Epidemiology Consulting Center, Center for Clinical Epidemiology and Biostatistics |
| 12:15pm | Panel Discussion / Q & A |
| 12:45pm | Lunch |
| 1:45pm | Small Fiber Neuropathy: Implications for Clinical Trials and Drug Development Roy Freeman, MD Professor of Neurology, Harvard Medical School; Director, Center for Autonomic and Peripheral Nerve Disorders, Beth Israel Deaconess Medical Center |
| 2:15pm | Panel Discussion / Q & A |
| 2:30pm | Phenotyping of Neuropathic Pain Patients: Implications for Clinical Trial Design and Drug Development Ralf Baron, MD Head, Division of Neurological Pain Research and Therapy; Vice Chair, Department of Neurology, Christian-Albrechts-Universitaet |
| 3pm | Panel Discussion / Q & A |
| 3:15pm | Break |
| 3:45pm | Mitigation of Placebo Response through Subject and Investigator Training Neil Singla, MD Chief Scientific Officer, Lotus Clinical Research |
| 4:15pm | Panel Discussion / Q & A |
The goals of this conference are:
- Gather world-renowned experts in clinical trials to convey and analyze current best practices.
- Disseminate the latest scientific and regulatory developments in topics of interest to the analgesic research industry.
- Discuss experimental methods that increase analgesic trial assay sensitivity.
- Involve audience members in dialogue with thought leaders in the field from regulatory bodies, industry, and academia.
- Convene at a familiar venue before the APS Annual Scientific Meeting to facilitate networking and future collaboration.
For questions or comments, please contact Clinical Trials SIG Chair Neil Singla, MD.
